Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|August 5, 2026 (Updated: July 30, 2026)

The BioPharm Brief: Platforms, Precision, and Patient Access

Listen
0:00 / 0:00

Today’s BioPharm Brief highlights new advances in engineered tissues, regenerative medicine, and biologics delivery, including clinical progress for a tissue-engineered therapy, late-stage wound healing data, and a major subcutaneous delivery licensing deal.

<iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8936510/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today, we’re looking at three stories spanning regenerative medicine, wound healing, and drug delivery technologies.

First, Satellite Bio has received FDA clearance for its Investigational New Drug application for SB-101, marking the company’s transition into the clinical stage. The candidate is based on Satellite Bio’s tissue-engineered platform, which is designed to create implantable tissues intended to restore or replace biological functions. The company plans to evaluate SB-101 in a clinical study as it advances its approach to engineered tissue therapeutics.

Next, Applied Biological Laboratories has reported phase III data for BioXheal in diabetic foot ulcers, a chronic wound condition associated with significant morbidity and healthcare burden. The company’s late-stage program is focused on evaluating BioXheal as a potential treatment option to support wound healing in patients with diabetic foot ulcers.

And finally, Alteogen has expanded the reach of its Hybrozyme platform through a subcutaneous delivery licensing agreement valued at up to $365 million. The technology uses recombinant human hyaluronidase to enable subcutaneous administration of biologics that are traditionally delivered intravenously. The deal highlights continued industry interest in delivery technologies that could improve convenience and potentially reduce treatment burden for patients receiving biologic therapies.

From engineered tissues entering the clinic to next-generation delivery platforms reshaping how biologics are administered, these stories highlight how innovation continues beyond the molecule itself.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Satellite Bio’s SB-101 IND clearance moves engineered tissue technology into clinical development.
  • Applied Biologicals is advancing BioXheal through late-stage evaluation for diabetic foot ulcers.
  • Alteogen’s Hybrozyme platform reflects continued momentum around subcutaneous delivery approaches for biologics.

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more